Abstract
4137 Background: ARQ 197 is a selective, non-ATP competitive inhibitor of c-MET, the exclusive receptor tyrosine kinase for hepatocyte growth factor implicated in tumor cell migration, invasion, proliferation and angiogenesis. Over-expression of c-Met and HGF is associated with poor prognosis in HCC pts. ARQ 197 has been evaluated in over 300 cancer pts. This study evaluates the safety, pharmacokinetics, biomarkers, and preliminary evidence of efficacy in HCC pts who received ≤ 2 prior systemic chemotherapy regimens. Methods: Multicenter, single cohort phase 1b trial. ARQ 197 is administered at the oral dose of 360 mg bid. Treatment is continued until disease progression or unacceptable toxicity. Results: As of December 31, 2009, 20 pts with HCC (2 F/ 18 M; range 47-80 median 69.9 years) were enrolled and treated. Of these, 12 and 8 pts presented with ECOG 1 and 0 respectively, while 16 and 4 pts presented with Child-Pugh A and B cirrhosis respectively. Drug- related adverse events (AEs) were reported in ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
